(±)-Verapamil hydrochloride

CHF 31.00
In stock
CDX-V0007-M100100 mgCHF 31.00
CDX-V0007-G0011 gCHF 62.00
CDX-V0007-G0055 gCHF 186.00
 
More Information
Product Details
Synonyms Manidon
Product Type Chemical
Properties
Formula C27H38N2O4 . HCl
MW 491.06
CAS 152-11-4
RTECS YV8320000
Source/Host Chemicals Synthetic
Purity Chemicals ≥99% (Titration)
Appearance White powder.
Solubility Soluble in methanol (50 mg/ml), ethanol or water.
Identity Determined by NMR.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key DOQPXTMNIUCOSY-UHFFFAOYSA-N
Smiles Cl.COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice Keep cool and dry.
Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at +4°C.
Documents
MSDS Inquire
Product Specification Sheet
Datasheet Download PDF
Verapamil hydrochloride is an α-adrenergic receptor (α-AR) antagonist and calcium channel protein inhibitor that blocks the L-type Ca2+ channels in smooth and cardiac muscle cells. Verapamil is an antiarrhythmic agent and vasodilator known to reduce the renal clearance of digoxin and induce apoptosis in primary and metastatic colon adenocarcinoma human cell lines in vitro. It has been observed that verapamil can induce currents by itself, presumably by acting on the potassium and chloride leakage. Verapamil has also been used as an inhibitor of drug efflux pump proteins such as Mdr (P-glycoprotein). Verapamil is a substrate of CYP3A4 and CYP2C6. It is also used in fluorescent cell sorting for DNA content, as it blocks efflux of a variety of DNA-binding fluorophores such as Hoechst 33342. Recent research has shown verapamil to be an effective treatment for diabetes in animal models. Verapamil helps treat diabetes by limiting TXNIP expression.
Product References
(1) A. Fleckenstein; Annu. Rev. Pharmacol. Toxicol. 17, 149 (1977) | (2) I.B. Shchepotin, et al.; Anticancer Res. 14, 1027 (1994) | (3) B.B. Lonsberry, et al.; Pharmacol. 49, 23 (1994) | (4) W.T. Bellamy; Annu. Rev. Pharmacol. Toxicol. 36, 161 (1996) | (5) T. Kantola, et al.; Clin. Pharmacol. Ther. 64, 177 (1998) | (6) M. Verschraagen, et al.; Pharmacol. Res. 40, 301 (1999) | (7) G. Xu, et al.; Diabetes. 61, 848 (2012)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.